Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Edwards Lifesciences Stops Enrollment in Heart Valve Trial - Medical Product Outsourcing

Edwards Lifesciences Stops Enrollment in Heart Valve Trial

A high prevalence of valve thrombosis prompted the halt.

Irvine, Calif.-based Edwards Lifesciences Corporation has halted enrollment in its Fortis clinical trial which was evaluating the Fortis heart valve. Subjects were developing blood clots, and company officials said they felt the occurrences warranted further investigation.

To date, the trial has treated more than 20 patients worldwide, all of whom had symptomatic mitral regurgitation and who were either compassionate cases or in one of Edwards Lifesciences’ high-risk registries.

The company reports it is working closely with trial investigators and Heart Teams to gather additional information in this early study of transcatheter mitral valve replacement therapy.

Edwards Lifesciences makes technology for heart valves and hemodynamic monitoring.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters